Faricimab

Class: Vascular Endothelial Growth Factor Antagonists
Brands: Vabysmo

Medically reviewed by Drugs.com on Mar 1, 2022. Written by ASHP.

Introduction

Faricimab-svoa is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor.

Uses for Faricimab

Faricimab-svoa has the following uses:

Faricimab-svoa is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Faricimab Dosage and Administration

General

Faricimab-svoa is available in the following dosage form(s) and strength(s):

Injection for intravitreal use: 120 mg/mL solution in a single-dose vial.

Dosage

It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

Dosage and Administration

For intravitreal injection. Faricimab must be administered by a qualified physician. Each vial should be used only for the treatment of a single eye.

• Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

  The recommended dose for faricimab-svoa is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44. Although additional efficacy was not demonstrated in most patients when faricimab-svoa was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.

• Diabetic Macular Edema (DME)

  Faricimab-svoa is recommended to be dosed by following one of these two dose regimens: 1) 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days ± 7 days, monthly) for at least 4 doses. If after at least 4 doses, resolution of edema based on the central subfield thickness (CST) of the macula as measured by optical coherence tomography is achieved, then the interval of dosing may be modified by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments based on CST and visual acuity evaluations through week 52; or 2) 6 mg dose of faricimab-svoa can be administered every 4 weeks for the first 6 doses, followed by 6 mg dose via intravitreal injection at intervals of every 8 weeks (2 months) over the next 28 weeks. Although additional efficacy was not demonstrated in most patients when faricimab-svoa was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.